Paul Saladino MD podcast cover image

250. When You Should Worry About LDL Cholesterol with Mike Fave

Paul Saladino MD podcast

NOTE

Efficacy of PCSK9 inhibitors in reducing mortality risk

A systematic review comparing PCSK9 inhibitors showed that while alirocumab reduced the risk of all cause mortality, evolocumab did not demonstrate the same effect. Specifically, evolocumab showed an 18% increased risk of mortality in lipid-lowering trials and a 12% increased risk in clinical outcome trials. The study also revealed a higher percentage of deaths in the evolocumab group compared to the placebo group, resulting in a number needed to harm of 213 over a median follow-up of 2.2 years.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner